Researchers at the University of Cambridge have announced that artificial intelligence has, for the first time, designed the core component of a new vaccine that has now entered human clinical trials. According to the research team, the technology could pave the way for the development of vaccines capable of providing protection against a broad range of viruses, thereby reducing the risk of future pandemics.
The vaccine has been engineered to offer protection against multiple members of the coronavirus family, including the virus responsible for COVID-19 as well as coronaviruses currently circulating in animal populations that could potentially spill over into humans and trigger future outbreaks.
To develop the vaccine, scientists compiled genetic data from numerous coronavirus strains and fed the information into an artificial intelligence system. After analyzing the data, the system designed a “super-antigen” intended to train the immune system to recognize and combat a wide spectrum of coronaviruses, even if they mutate or undergo significant structural changes.
Professor Jonathan Heeney, one of the lead researchers on the project, said this marks the first time that an AI-designed antigen has been used in human clinical testing. He noted that the ultimate goal of the technology is to create vaccines capable of protecting people not only against existing viruses but also against future viral threats.
The initial phase of the study involved 39 volunteers and was primarily designed to assess the vaccine’s safety profile. The next phase is expected to enroll approximately 200 participants, enabling researchers to evaluate more precisely how effectively the vaccine trains and strengthens the immune response.
Preliminary findings, published in the journal Infectious Diseases, indicate that the vaccine generated a moderate immune response. Nevertheless, researchers and public health experts have described the achievement as a significant milestone in the development of next-generation vaccines.
Scientists at the University of Cambridge are now applying the same AI-driven approach to vaccines targeting diseases such as seasonal influenza, avian influenza, and Ebola. The objective is to develop vaccines that require less frequent updating while providing broader protection against diverse viral strains.
A number of independent experts have also characterized the findings as highly encouraging. They believe that artificial intelligence has the potential to accelerate vaccine design and development and could play a pivotal role in preventing future infectious disease outbreaks and saving lives worldwide.
Writer:Salima Aryaei
